<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734214</url>
  </required_header>
  <id_info>
    <org_study_id>07-265</org_study_id>
    <nct_id>NCT00734214</nct_id>
  </id_info>
  <brief_title>Hypotonic Versus Isotonic Parenteral (HIP) Fluid Trial</brief_title>
  <official_title>Hypotonic Versus Isotonic Parenteral Fluids in Children - a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children who are undergoing surgery need intravenous fluids to prevent dehydration and
      maintain their electrolyte balance. The current standard of care in these children is to use
      a fluid which is low in sodium (hypotonic fluid). The safety of this practice has never been
      tested. There is ongoing concern from the medical community that this type of fluid increases
      the child's risk of developing low sodium levels, and hence may not be safe for all children.
      Low sodium can lead to significant complications such as seizures, coma and even death, risks
      of which are often underestimated and not anticipated by their caregivers. Experts in the
      field suggest that giving a solution with a similar sodium content to that of blood (isotonic
      fluid) reduces the risk of these problems in these children. This study will compare these
      two types of intravenous fluids (hypotonic versus isotonic), in a blinded fashion (i.e.
      neither the patient nor caregivers or investigators will be aware which type of fluid the
      patient is receiving), in children following surgery. The investigators goal is to see which
      type of fluid is safer, and leads to more stable sodium levels. This would in turn lead to a
      lower risk of complications as described above.

      This is the first time such a study is preformed in pediatrics. There are unnecessary number
      of complications and potential deaths from this disorder, and hence the safety of everyday
      fluid practice in children needs to be scientifically tested. The results of this study will
      enable the investigators to propose scientifically based guidelines on how to minimize risks
      associated with intravenous infusions in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research Question:

      In general pediatric surgical patients, do isotonic PMS compared to hypotonic PMS, result in
      a lower risk of acute hospital acquired plasma sodium derangements, occurring at any time
      during the study intervention? Primary efficacy objective -To determine the impact of
      postoperative administration of isotonic compared to hypotonic PMS on the risk of hospital
      acquired PNa derangements in pediatric surgical patients, occurring at any time during the
      study intervention.

      Secondary efficacy objectives: a) To determine the impact of postoperative administration of
      isotonic compared to hypotonic PMS on clinical sequelae related to acute PNa changes, in
      pediatric surgical patients. b) the independent predictors of hospital acquired PNa
      derangements will be explored.

      Study Design:

      This is a double-blind randomized controlled trial. Participants, health care providers, data
      collectors, and judicial assessors of outcomes will be blinded to the study intervention.

      Setting: McMaster Children's Hospital.

      Trial Intervention:

      Enrolled patients will be randomized postoperatively to receive either one of the following
      parenteral maintenance solutions: 1) hypotonic PMS, or 2) isotonic PMS. For the purposes of
      this study the hypotonic PMS will be 0.45%NaCl, and the Isotonic PMS will be 0.9% NaCl.
      Enrolled patients will receive their allocated treatment (provided there are no safety issues
      or concerns) until they are fully orally fed and the PMS rate is no greater than a rate
      required to &quot;keep vein open (KVO)&quot;, to a maximum duration of 48 hours. The physician can
      thereafter administer the maintenance solution of their choice. The following parameters will
      be monitored in each study participant during the treatment period: hourly urine output,
      strict intake and output, 12 hourly fluid balances and daily weights. Blood and urine samples
      will be obtained on study patients every 12 hours until they are fully orally fed and the IV
      rate is at KVO, for a maximum of 48 hours. Any additional investigations ordered by the
      caring physician during the treatment and follow up period will also be recorded. Patients
      will be followed for clinical outcomes for 48 hours after the study intervention is
      discontinued, or until the time of discharge.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital Acquired Acute Plasma Sodium Derangements (Hypo- or Hypernatremia)</measure>
    <time_frame>During the treatment and follow-up period.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hyponatremia</measure>
    <time_frame>during the study intervention</time_frame>
    <description>Plasma sodium less than 135 mmol/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Morbidity Attributed to Acute Plasma Sodium Changes.</measure>
    <time_frame>During the treatment and follow-up period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Hyponatremia</condition>
  <condition>Hypernatremia</condition>
  <arm_group>
    <arm_group_label>0.9% NaCl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.45% NaCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% NaCl</intervention_name>
    <description>Intravenous Fluid
Isotonic Parenteral Fluid</description>
    <arm_group_label>0.9% NaCl</arm_group_label>
    <other_name>Isotonic saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.45%NaCl</intervention_name>
    <description>Intravenous Fluid
Hypotonic Parenteral Fluid</description>
    <arm_group_label>0.45% NaCl</arm_group_label>
    <other_name>Hypotonic saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric patients, 6 months corrected age -16 years, undergoing surgery.

          -  Within 6 hours of the immediate post-operative period.

          -  Post-operative stay anticipated to be more than 24 hours.

          -  Primary route of fluid administration is anticipated to be intravenous, in the first
             24 hours following surgery.

          -  Informed consent of parent/guardian.

          -  Consent to participate from surgeon.

        Exclusion Criteria:

          -  Patients under 6 months of age

          -  Patients equal to or over 17 years of age

          -  Patients with hemodynamic instability , defined as a requirement for continuous
             vasoactive infusion (e.g. epinephrine, dopamine, norepinephrine, phenylephrine,
             milrinone, or Dobutamine) to maintain blood pressure at the end of surgery.

          -  Patients admitted into the &quot;short stay&quot; post-operative unit

          -  Patients in whom either hypotonic or isotonic solutions may be
             contraindicated/necessary: i.e. specific neurosurgical patients (ie those at risk of
             increased ICP, e.g. requiring actual brain surgery, ICP monitor or external
             ventricular drain insertion), patients with diabetic ketoacidosis, acute (≤ 7 days)
             burns, pre-existing CHF, liver failure or cirrhosis, renal failure.

          -  Patients with known pre-existing risk of PNa derangements: DI or SIADH

          -  Chronic diuretic use - defined as use of any oral or intravenous diuretics for ≥ 7
             days.

          -  Known, uncorrected PNa derangement (PNa &lt; 134 or &gt; 146 mmol/L), identified
             peri-operatively (i.e. within 12 hours of surgery or during surgery).

          -  Prior enrolment in this study

          -  Patients or their guardians objecting to give consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Choong, MB, BCh, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster Children's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <results_first_submitted>May 11, 2012</results_first_submitted>
  <results_first_submitted_qc>May 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 13, 2012</results_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parenteral Fluids</keyword>
  <keyword>Isotonic</keyword>
  <keyword>Hypotonic</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Fluid overload</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
    <mesh_term>Hypernatremia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0.9% NaCl</title>
        </group>
        <group group_id="P2">
          <title>0.45% NaCl</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>MD withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.9% NaCl</title>
        </group>
        <group group_id="B2">
          <title>0.45% NaCl</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="128"/>
            <count group_id="B2" value="130"/>
            <count group_id="B3" value="258"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.2" spread="5.5"/>
                    <measurement group_id="B2" value="9.2" spread="5.7"/>
                    <measurement group_id="B3" value="9.2" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hospital Acquired Acute Plasma Sodium Derangements (Hypo- or Hypernatremia)</title>
        <time_frame>During the treatment and follow-up period.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Morbidity Attributed to Acute Plasma Sodium Changes.</title>
        <time_frame>During the treatment and follow-up period</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hyponatremia</title>
        <description>Plasma sodium less than 135 mmol/L</description>
        <time_frame>during the study intervention</time_frame>
        <population>Intention to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>0.9% NaCl</title>
          </group>
          <group group_id="O2">
            <title>0.45% NaCl</title>
          </group>
        </group_list>
        <measure>
          <title>Hyponatremia</title>
          <description>Plasma sodium less than 135 mmol/L</description>
          <population>Intention to treat analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>0.9% NaCl</title>
        </group>
        <group group_id="E2">
          <title>0.45% NaCl</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>New onset hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>New onset Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized Edema</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="128"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Karen Choong</name_or_title>
      <organization>McMaster University</organization>
      <phone>905-5212100 ext 75617</phone>
      <email>choongk@mcmaster.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

